GlassScriptPhysician profile
Raul T Meoz
NPI 1831108257
$2,926.82
in general payments reported to CMS, 2019-2025
32 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2022: $293 · 2023: $838 · 2024: $1,215 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $629.85 | 2024-2025 | Enhertu, Injectafer |
| Exelixis INC. | $416.15 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $287.44 | 2023-2025 | |
| Visionrt, INC. | $199.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $152.04 | 2023-2024 | Libtayo |
| Icotec Medical INC. | $123.74 | 2024 | Vader Pedicle System |
| Astrazeneca Pharmaceuticals LP | $115.09 | 2023-2024 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $107.98 | 2023 | |
| Progenics Pharmaceuticals, INC. | $97.76 | 2022 | |
| Novocure INC. | $96.68 | 2022 | |
| Pfizer INC. | $72.60 | 2023-2024 | |
| Stemline Therapeutics INC. | $50.42 | 2023-2024 | Orserdu |
| Seagen INC. | $49.34 | 2023 | Padcev |
| Sobi, INC | $48.18 | 2024 | |
| Incyte Corporation | $39.12 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $38.25 | 2023-2024 | Krazati |
| Lilly USA, LLC | $37.26 | 2022 | |
| Janssen Biotech, INC. | $35.68 | 2023-2024 | Erleada, Carvykti |
| Genzyme Corporation | $33.48 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.29 | 2023 | Gilotrif |
| Tempus Ai, INC | $29.79 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $28.43 | 2024 | Keytruda |
| Eisai INC. | $24.17 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $22.78 | 2023 | Somatuline Depot, Onivyde |
| Celgene Corporation | $22.41 | 2022 | |
| Glaxosmithkline, LLC. | $21.72 | 2025 | Jemperli |
| Genentech USA, INC. | $21.59 | 2023 | Tecentriq |
| Abbvie INC. | $21.54 | 2024 | |
| Amgen INC. | $18.73 | 2023 | Lumakras |
| Sumitomo Pharma America, INC. | $18.38 | 2023 | Orgovyx |
| Kyowa Kirin, INC. | $18.34 | 2023 | Poteligeo |
| Coherus Oncology, INC. | $16.34 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Meoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.